Chen CS - Search Results

1

Characterization of three growth hormone-responsive transcription factors preferentially expressed in adult female liver.

Laz EV, Holloway MG, Chen CS, Waxman DJ. Laz EV, et al. Among authors: chen cs. Endocrinology. 2007 Jul;148(7):3327-37. doi: 10.1210/en.2006-1192. Epub 2007 Apr 5. Endocrinology. 2007. PMID: 17412818 Free PMC article.

2

Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.

Chen CS, Jounaidi Y, Waxman DJ. Chen CS, et al. Drug Metab Dispos. 2005 Sep;33(9):1261-7. doi: 10.1124/dmd.105.004788. Epub 2005 May 26. Drug Metab Dispos. 2005. PMID: 15919850

3

Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.

Schwartz PS, Chen CS, Waxman DJ. Schwartz PS, et al. Among authors: chen cs. Cancer Res. 2002 Dec 1;62(23):6928-37. Cancer Res. 2002. PMID: 12460909

4

Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.

Schwartz PS, Chen CS, Waxman DJ. Schwartz PS, et al. Among authors: chen cs. Cancer Gene Ther. 2003 Aug;10(8):571-82. doi: 10.1038/sj.cgt.7700601. Cancer Gene Ther. 2003. PMID: 12872138

5

Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.

Chen CS, Lin JT, Goss KA, He YA, Halpert JR, Waxman DJ. Chen CS, et al. Mol Pharmacol. 2004 May;65(5):1278-85. doi: 10.1124/mol.65.5.1278. Mol Pharmacol. 2004. PMID: 15102956

6

Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice.

Cheung C, Yu AM, Chen CS, Krausz KW, Byrd LG, Feigenbaum L, Edwards RJ, Waxman DJ, Gonzalez FJ. Cheung C, et al. Among authors: chen cs. J Pharmacol Exp Ther. 2006 Mar;316(3):1328-34. doi: 10.1124/jpet.105.094367. Epub 2005 Nov 16. J Pharmacol Exp Ther. 2006. PMID: 16291874

7

Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.

Jounaidi Y, Chen CS, Veal GJ, Waxman DJ. Jounaidi Y, et al. Among authors: chen cs. Mol Cancer Ther. 2006 Mar;5(3):541-55. doi: 10.1158/1535-7163.MCT-05-0321. Mol Cancer Ther. 2006. PMID: 16546968

8

Antiangiogenesis enhances intratumoral drug retention.

Ma J, Chen CS, Blute T, Waxman DJ. Ma J, et al. Among authors: chen cs. Cancer Res. 2011 Apr 1;71(7):2675-85. doi: 10.1158/0008-5472.CAN-10-3242. Epub 2011 Mar 29. Cancer Res. 2011. PMID: 21447737 Free PMC article.

9

Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.

Chen CS, Doloff JC, Waxman DJ. Chen CS, et al. Neoplasia. 2014 Jan;16(1):84-96. doi: 10.1593/neo.131910. Neoplasia. 2014. PMID: 24563621 Free PMC article.

10

Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.

Doloff JC, Chen CS, Waxman DJ. Doloff JC, et al. Among authors: chen cs. Mol Cancer. 2014 Jun 26;13:158. doi: 10.1186/1476-4598-13-158. Mol Cancer. 2014. PMID: 24965046 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,559 results

Search Page

Filters